Holen Sie sich die Stockscreener-App
21.04
2.14%
-0.46
Handel nachbörslich:
21.15
0.11
+0.52%
Kailera Therapeutics Inc Aktie (KLRA) Neueste Nachrichten
How AI is Transforming Health Literacy and Engagement - William Blair
RTW Bio NAV Rises 7.0% In April As Biotech IPO And M&A Activity Accelerates - DirectorsTalk Interviews
Evercore Initiates Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
TD Cowen Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
Kailera Therapeutics, Inc. (KLRA) Total Expenses (TTM) - Zacks Investment Research
What's Going On With Kailera Therapeutics Stock Wednesday?Kailera Therapeutics (NASDAQ:KLRA) - Benzinga
Kailera Therapeutics, Inc. (KLRA) Profit Margin (Quarterly) - Zacks Investment Research
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions - ChartMill
Kailera Therapeutics, Inc. (KLRA) Dividend Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Market Cap - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value (Per Share) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (Quarterly) - Zacks Investment Research
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Kailera's record IPO headlines strong April for biopharma financings - BioWorld News
A Quick Look at Today's Ratings for Kailera Therapeutics(KLRA.US), With a Forecast Between $30 to $48 - Moomoo
Kailera Therapeutics (KLRA) Stock Forecast and Price Target 2026 $KLRA - MarketBeat
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target - marketscreener.com
Evercore ISI Kailera Therapeutics Initiates at Outperform - Moomoo
Investment bank Leerink Partners announces the initiation of research coverage on biopharmaceutical company Kailera Therapeutics. - Bitget
TD Cowen initiates Kailera stock with buy on weight loss drug potential - Investing.com Canada
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
William Blair initiates Kailera stock with Outperform rating By Investing.com - Investing.com Canada
JPMorgan initiates Kailera stock at Overweight on obesity pipeline By Investing.com - Investing.com Canada
This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Dividend (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Free Cash Flow (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Total Long Term Debt (Quarterly) - Zacks Investment Research
Odyssey raises $304 million in upsized Nasdaq debut - The Pharma Letter
Kailera Therapeutics, Inc. (KLRA) Price To Free Cash Flow - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Profit (TTM) - Zacks Investment Research
KLRA: Kailera Therapeutics, Inc.12 Month EPS - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Earnings Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Return On Equity (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
KLRA : Kailera Therapeutics, Inc. Key Company Details - Zacks Investment Research
IPO Tracker 2026: Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq - BioSpace
Kailera Therapeutics, Inc. (KLRA) Debt Equity Ratio (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Cash From Operations (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value - Zacks Investment Research
Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debut - WNWN-FM
Kailera Therapeutics, Inc. Stock Data and SignalsKLRA - StockInvest.us
Kailera Therapeutics, Inc. (KLRA) Total Liabilities - Zacks Investment Research
Number of shareholders of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Cash From Financing (Quarterly) - Zacks Investment Research
Biotech firm Odyssey raises $279 million in upsized US IPO - 102.7 WBOW
Kailera Therapeutics, Inc. (KLRA) Price To Cash Flow - Zacks Investment Research
Kailera Therapeutics (KLRA) Stock Analysis Report | Financials & Insights - Benzinga
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Kailera Therapeutics debut marks largest biotech IPO since 2021 amid weight loss race - MSN
Biotech firm Odyssey targets $810 million valuation in US IPO - WHTC
Kailera Therapeutics IPO And Governance Shift Draw Investor Attention - Sahm
Kailera IPO And Governance Overhaul Set Terms For NASDAQ Composite Debut - Yahoo Finance
GLP-1 developer Kailera prices IPO at $16 per share to raise $625M - MSN
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):